SEC Form 4 · accession 0001171843-18-002392
ARGOS THERAPEUTICS INC · ARGS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles A. Nicolette
Officer — CSO and Vice President of R&D
Period of report
Mar 28, 2018
Accepted (ET)
Mar 30, 2018 · 5:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001105533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 28, 2018 | A | 27,150 | $0.00 | A | 47,206 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares are subject to a lapsing right of repurchase by the issuer, which shall lapse as to 13,575 shares on June 15, 2018, and with respect to the remaining 13,575 shares on December 14, 2018, subject to the Reporting Person continuing to be an employee of the issuer through each such date.